News Releases
FDA Approves Injectable Wireless Device for Back and Leg Pain
Stimwave Technologies Incorporated, a medical device manufacturer and independent research institute headquartered in Miami Beach, Fla., has received FDA clearance to market the world’s first wireless, micro-technology neuromodulation device for relief of chronic back and leg pain.
FDA Approves Extended-Release, Single-Entity Hydrocodone Product
The US Food and Drug Administration today approved Zohydro ER (hydrocodone bitartrate extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate.
New Drug Application for Amitiza Approved
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals USA, Inc. announced today that the FDA has approved Sucampo’s supplemental new drug application (sNDA) for AMITIZA ® (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
Pfizer Stops Phase 3 Trial Of Lyrica
Pfizer Inc. announced that it has stopped a Phase 3 clinical trial of Lyrica ( pregabalin ) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet.
Pfizer Announces New Drug Application For Tofacitinib
Pfizer Inc.announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690 ,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Pfizer and Acura Announce FDA Approval of Oxecta
Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM (oxycodone HCl, USP) Tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
Faster Acting Aspirin Hits the Market
When you have a headache, a toothache or the cramps, all you want is fast pain relief. Now there’s a new form of aspirin that’s twice as fast as what you’ve been using. Bayer Healthcare has launched a new generation of aspirin.